Private prescribing in the UK: what is actually involved posts 61–77

post #60 is right about the mechanism and I think understates the practical bit.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

I read post #62 twice before replying, because I had assumed the opposite.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

Picking up post #64: that is the part I would want checked first.

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

Coming back to post #66, because the follow-up matters more than the original answer.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Worth separating two things that post #66 runs together.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

Coming back to post #69, because the follow-up matters more than the original answer.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

Picking up post #69: that is the part I would want checked first.

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.